Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis
- PMID: 19042012
- DOI: 10.1016/S0140-6736(08)61762-6
Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis
Erratum in
- Lancet. 2009 Feb 21;373(9664):632
Abstract
Background: WHO and Health Action International (HAI) have developed a standardised method for surveying medicine prices, availability, affordability, and price components in low-income and middle-income countries. Here, we present a secondary analysis of medicine availability in 45 national and subnational surveys done using the WHO/HAI methodology.
Methods: Data from 45 WHO/HAI surveys in 36 countries were adjusted for inflation or deflation and purchasing power parity. International reference prices from open international procurements for generic products were used as comparators. Results are presented for 15 medicines included in at least 80% of surveys and four individual medicines.
Findings: Average public sector availability of generic medicines ranged from 29.4% to 54.4% across WHO regions. Median government procurement prices for 15 generic medicines were 1.11 times corresponding international reference prices, although purchasing efficiency ranged from 0.09 to 5.37 times international reference prices. Low procurement prices did not always translate into low patient prices. Private sector patients paid 9-25 times international reference prices for lowest-priced generic products and over 20 times international reference prices for originator products across WHO regions. Treatments for acute and chronic illness were largely unaffordable in many countries. In the private sector, wholesale mark-ups ranged from 2% to 380%, whereas retail mark-ups ranged from 10% to 552%. In countries where value added tax was applied to medicines, the amount charged varied from 4% to 15%.
Interpretation: Overall, public and private sector prices for originator and generic medicines were substantially higher than would be expected if purchasing and distribution were efficient and mark-ups were reasonable. Policy options such as promoting generic medicines and alternative financing mechanisms are needed to increase availability, reduce prices, and improve affordability.
Comment in
-
Essential medicines pricing--reform needed.Lancet. 2009 Jan 17;373(9659):191-3. doi: 10.1016/S0140-6736(08)61763-8. Epub 2008 Nov 29. Lancet. 2009. PMID: 19042013 No abstract available.
-
Better measures of affordability required.Lancet. 2009 Mar 28;373(9669):1081; author reply 1081-2. doi: 10.1016/S0140-6736(09)60649-8. Lancet. 2009. PMID: 19329001 No abstract available.
Similar articles
-
Prices, availability, and affordability of adult medicines in 54 low-income and middle-income countries: evidence based on a secondary analysis.Lancet Glob Health. 2025 Jan;13(1):e50-e58. doi: 10.1016/S2214-109X(24)00442-X. Lancet Glob Health. 2025. PMID: 39706661
-
Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.Lancet Glob Health. 2013 Oct;1(4):e227-37. doi: 10.1016/S2214-109X(13)70072-X. Epub 2013 Sep 24. Lancet Glob Health. 2013. PMID: 25104348
-
Prices & availability of common medicines at six sites in India using a standard methodology.Indian J Med Res. 2007 May;125(5):645-54. Indian J Med Res. 2007. PMID: 17642500
-
High medicine prices and poor affordability.Curr Opin Psychiatry. 2011 Jul;24(4):341-5. doi: 10.1097/YCO.0b013e3283477b68. Curr Opin Psychiatry. 2011. PMID: 21532479 Review.
-
Access to cardiovascular medicines in low- and middle-income countries: a mini review.Glob Health Res Policy. 2023 May 23;8(1):17. doi: 10.1186/s41256-023-00301-6. Glob Health Res Policy. 2023. PMID: 37221559 Free PMC article. Review.
Cited by
-
Cross-sectional Study on the Impact of Discount Pricing and Price Competition on Community Pharmacy Practice.Cureus. 2020 Aug 20;12(8):e9903. doi: 10.7759/cureus.9903. Cureus. 2020. PMID: 32839684 Free PMC article.
-
Availability and Price Variations of Commonly Used Cardiovascular Medicines at Community and Hospital Pharmacies in Gondar Town, Northwest Ethiopia.Biomed Res Int. 2024 Sep 17;2024:6551639. doi: 10.1155/2024/6551639. eCollection 2024. Biomed Res Int. 2024. PMID: 39318399 Free PMC article.
-
Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries.Circulation. 2016 May 24;133(21):2076-85. doi: 10.1161/CIRCULATIONAHA.115.008722. Circulation. 2016. PMID: 27217433 Free PMC article. Review.
-
Access to Essential Medicines and Diagnostic Tests for Cardiovascular Diseases in Maputo City, Mozambique.Glob Heart. 2023 Feb 28;18(1):8. doi: 10.5334/gh.1186. eCollection 2023. Glob Heart. 2023. PMID: 36874443 Free PMC article.
-
A cross sectional comparison of drug use indicators using WHO methodology in primary level hospitals participating in an Auditable Pharmaceutical Transactions and Services program versus non-APTS primary hospitals in Southern Ethiopia.PLoS One. 2019 Oct 7;14(10):e0223523. doi: 10.1371/journal.pone.0223523. eCollection 2019. PLoS One. 2019. PMID: 31589641 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources